Vickers Venture Partners snags $285m for sixth fund

Its portfolio includes a firm working on a vaccine against COVID-19.

Singapore-based Vickers Venture Partners received commitments amounting to $285.48m (US$200m) for its target $713.69m (US$500m) Fund VI, according to a press release. This excludes general partner commitments.

The company aims it to be the largest non-government linked venture capital fund raised by a VC firm based in Southeast Asia.

Vickers’ portfolio so far comprises companies such as geothermal solutions startup Eavor, medtech decacorn Samumed and bioplastics firm RWDC Industries. It is also funding vaccine company Emergex, which is working on developing vaccinations against COVID-19.

Vickers Venture Partners is a venture capital firm focused on early-stage investments in Asia. The firm’s portfolio covers life sciences, technology, media, and telecommunications as well as consumer and financial services.

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia